27. Business combinations during the prior period
On 21 June 2022 we acquired, in an all-cash transaction, 100% of the shares and voting interests of CellPoint for a total agreed payment at completion of €125 million, including consideration for other liabilities associated with the transaction amounting to €10.3 million. Additional contingent consideration up to €100.0 million is due when certain milestones would be achieved.
On the same date we acquired all of the outstanding capital of AboundBio, for a total agreed price of $14 million, including consideration for other liabilities associated with the transaction.
The main reason for these acquisitions was to position ourselves in the next-generation cancer therapy market and to significantly broaden our portfolio and capabilities. The goal is to expand the current market for CAR-T therapies and have an important impact on patients in need of additional and improved treatment options.
Details of the fair value of identifiable assets and liabilities acquired in both transactions, the purchase consideration, the goodwill at the acquisition date and the net cash outflow arising on acquisition are as follows:
|
21 June 2022 |
|
|||||
---|---|---|---|---|---|---|---|
|
CellPoint |
AboundBio |
Total |
||||
(thousands of €) |
Book value |
Adjustment |
Fair value |
Book value |
Adjustment |
Fair value |
|
Intangible assets other than goodwill |
- |
120,517 |
120,517 |
- |
4,053 |
4,053 |
|
Property, plant and equipment |
1,289 |
|
1,289 |
965 |
|
965 |
|
Other non-current assets |
81 |
|
81 |
4 |
|
4 |
|
Trade and other receivables |
162 |
|
162 |
- |
|
- |
|
Cash and cash equivalents |
3,179 |
|
3,179 |
4,279 |
|
4,279 |
|
Other current assets |
1,254 |
|
1,254 |
536 |
|
536 |
|
Deferred tax liabilities |
- |
(22,368) |
(22,368) |
- |
(907) |
(907) |
|
Trade and other liabilities |
(32,789) |
|
(32,789) |
(587) |
|
(587) |
|
Current deferred income |
- |
|
- |
(474) |
|
(474) |
|
Net assets acquired |
(26,824) |
98,149 |
71,325 |
4,723 |
3,146 |
7,869 |
|
Consideration paid in cash |
|
|
107,750 |
|
|
14,976 |
|
Fair value re-measurement of previously held equity investment |
|
|
|
|
|
342 |
|
Deferred consideration |
|
|
5,808 |
|
|
- |
|
Fair value of contingent consideration |
|
|
20,211 |
|
|
- |
|
Fair value of total consideration |
|
|
133,769 |
|
|
15,318 |
|
|
|
|
|
|
|
|
|
Goodwill |
|
|
62,444 |
|
|
7,449 |
|
Exchange differences on goodwill |
|
|
|
|
|
(80) |
|
Goodwill in the balance sheet at 31 December 2022 |
|
|
62,444 |
|
|
7,369 |
69,813 |
|
|
|
|
|
|
|
|
Net cash outflow arising on acquisition |
|
|
|
|
|
|
|
Consideration paid in cash |
|
|
107,750 |
|
|
14,976 |
|
Less: cash and cash equivalents balances acquired |
|
|
(3,179) |
|
|
(4,279) |
|
Cash out from acquisition of subsidiaries, net of cash acquired (in 2022) |
|
|
104,571 |
|
|
10,698 |
115,270 |
|
|
|
|
|
|
|
|
Cash used in operating activities for other liabilities related to the acquisition of subsidiaries (paid in 2022) |
|
|
28,164 |
|
|
|
28,164 |
|
|
|
|
|
|
|
|
Cash out from acquisition of subsidiaries (payment of deferred consideration in 2023) |
|
|
7,000 |
|
|
|
7,000 |
As part of the acquisitions, we identified the following acquired intangible assets:
- IPR&D: in-process research and development related to two CD19 CAR-T product candidates in Phase 1/2a clinical studies. The fair value at acquisition date (€28.2 million) was based on the relief from royalty method.
- Exclusive rights: through the acquisition of CellPoint we acquired on the one hand a collaboration agreement between CellPoint and Lonza providing the exclusive right to use the automated Lonza Cocoon® Platform in the development and commercialization of CAR-T cell products, and secondly, a collaboration agreement between CellPoint and Hypertrust providing exclusivity to use the jointly developed XCellit® software for workflow management and monitoring for the manufacturing of the CAR-T cells using the Lonza Cocoon® Platform. The fair values at acquisition date amounted to €89.7 million and €2.6 million respectively. A with and without method was retained to value the exclusivity with Lonza and the XCellit® software was valued based on the applicable royalty rate in the contract.
- Technology: through the acquisition of AboundBio, we acquired a fully human antibody-based therapeutics platform which was valued at €4.1 million at the time of acquisition.
We assessed that the carrying value of all other acquired assets and assumed liabilities approximate their fair value at acquisition date.
The goodwill arising from both transactions totaling €69.8 million was attributable to buyer specific synergies, the value of the assembled workforce and the accounting for net deferred tax liabilities for a total amount of €23.3 million, consisting of deferred tax liabilities on the acquired intangible assets of €32.3 million less recognized deferred tax assets of €9.0 million.
The acquisition costs related to both transactions were considered not to be material and were recognized in our consolidated income statement on the line "general & administrative expenses”.